Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202510022 A preliminary, four-period, fully-replicated, crossover bioequivalence study to compare two tacrolimus PR capsules in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
N202510028 A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High- Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02) New Drug Phase Ⅲ
N202510037 A randomized, open-label, three-period, reference-replicated, crossover bioequivalence study to compare two agomelatine F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202510050 A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non- Hospitalized Adults With COVID-19 at High Risk for Disease Progression New Drug Phase Ⅲ
N202510051 A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non- Hospitalized Adults With COVID-19 at High Risk for Disease Progression New Drug Phase Ⅲ
N202510058 A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer New Drug Phase Ⅰ
N202510059 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD) New Drug Phase Ⅲ
N202510061 A phase 1, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HCB301 in subjects with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas New Drug Phase Ⅰ
N202510066 A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers New Drug Phase Ⅲ
N202510067 A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age New Drug Phase Ⅱ
1 2 33 34 35 36 37 38 39 51 52 / 52

TOP